Clinical Trial Update: Henagliflozin on Liver Fibrosis in Patients with MASLD and T2DM [Phase 4]

View source ↗

Summary

Phase 4 clinical trial update evaluating henagliflozin for liver fibrosis in patients with MASLD and type 2 diabetes; the study is currently not yet recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Metabolic Dysfunction-associated Steatotic Liver Disease
• Type 2 Diabetes Mellitus

Drugs mentioned

• Henagliflozin (henagliflozin)

Snippet

Sponsor: Xiqiao Zhou | Conditions: Metabolic Dysfunction-associated Steatotic Liver Disease, Type 2 Diabetes Mellitus | Phase 4 | Status: NOT_YET_RECRUITING